Filtered By:
Source: Value in Health
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
CO8 Design and Rationale of a Global Prospective Observational Study of Real-World Management of Patients with Atrial Fibrillation at High Risk of Stroke- Gardenia
Anticoagulants reduce the risk of stroke in patients with atrial fibrillation (AF). However, due to various causes, including concerns for bleeding, there is treatment variability, including undertreatment or non-treatment, especially in patients with high bleeding risk. The aim of the GARDENIA registry is threefold, 1) to understand the real-world usage of oral anticoagulants (OAC) in patients with AF and elevated risk of bleeding, 2) to evaluate the factors associated with treatment or non-treatment with OACs and adherence to guideline recommended doses of OACs and 3) to determine the incidence of clinical outcomes in th...
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: A. Kakkar, M. Bonaca, R.P. Giugliano, D. Bloomfield, K. Pieper, B.A. Yi, J. Salter, D. Freedholm, S. Parkar, J. Glasspool, G. Kayani, K.A.A. Fox Source Type: research
CO4 Outcomes of Non –Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies
This study aimed to ident ify differences between original studies of NOACs vs warfarin to support interpretation of results across studies.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: R. Wang, H. Lien, A. Borrow, D. Fleishman Source Type: research
CO1 Psychosocial Disorders and Clinical Outcomes Among Older Adults with Atrial Fibrillation: The Sage-AF Study
To examine the association between anxiety, depression, or both, and clinical outcomes, including mortality, stroke, major bleeding, and hospitalizations, among older adults with atrial fibrillation (AF).
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: A. Hamel, J. Mehawej, A. Filippaios, K. John, A. Mishra, H.O. Abu, D. Lessard, M. Tisminetzky, W. Wang, K.V. Tran, T. Paul, J. Saczynski, D. McManus Tags: Clinical Outcomes Source Type: research
EE344 Cost-Effectiveness of a Novel Treatment for Stroke Prevention in Patients with Atrial Fibrillation: Results from an Early Economic Analysis
For many patients with atrial fibrillation (AF) at moderate-to-high risk of stroke, clinically significant bleeding from anticoagulants remains a concern, leading to withholding or discontinuation of anticoagulation. Patients who are unsuitable for or inadequately treated with currently available anticoagulants remain at higher risk for stroke and systemic embolism. This early economic analysis explored the potential cost-effectiveness of a hypothetical new therapy that reduces the risk of stroke in patients with AF who are unsuitable for treatment with currently available anticoagulants.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: J. Benner, D. Bloomfield, N. Mehta, B.A. Yi Source Type: research
EE411 Healthcare Costs of Direct Oral Anticoagulants Among Medicare Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
To evaluate cost differences between stroke/systemic embolism (S/SE) and major bleeding (MB) among nonvalvular atrial fibrillation (NVAF) patients with multimorbidity prescribed direct oral anticoagulants (DOACs) or warfarin.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: AD Dhamane, M Ferri, A Keshishian, C Russ, N Atreja, R Thomas, G Leung, B Emir, H Yuce, M DiFusco Source Type: research
PCV44 Real-World Assessment of the Use of Anti-platelet Therapy for Recurrent Stroke Prevention in US Patients without Atrial Fibrillation with Recent Ischemic Stroke or Transient Ischemic Attack
This study evaluated current AP treatment patterns in a real-world setting following an initial ischemic stroke (IS) or transient ischemic attack (TIA).
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: E. O'Brien, D. Milentijevic, R. Roychowdhury, S. Mitra, Y.W. Chen Source Type: research
PCV42 Antiplatelet Treatment Patterns for Secondary Stroke Prevention in the United Kingdom
This study evaluated outpatient antiplatelet treatment patterns for secondary stroke prevention (SSP) after first hospitalization for IS/TIA among UK adults without atrial fibrillation (AF).
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: J. Jiang, D. Li, J. Horrow, H. Tamada, A. Kahl, V. Hariharan, A. Avinav, X. Liu, X. Li Tags: Cardiovascular Disorders - Health Service Delivery & Process of Care Source Type: research
PCV22 Estimating the Reduction in Medical Care Costs Associated with Ticagrelor and Aspirin in Patients with Acute Ischemic Stroke or TIA
The efficacy of ticagrelor 90mg and aspirin (ticagrelor-aspirin) for the prevention of stroke following an ischaemic stroke (IS) or transient ischaemic attack (TIA) was evaluated in the Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death (THALES, NCT03354429) trial. Ticagrelor-aspirin resulted in a 17% reduction in the risk of stroke or death over 30 days versus aspirin, but with more bleeding events. Ticagrelor 90mg is approved to reduce stroke risk in patients with acute IS (NIH Stroke Scale score ≤5) or high-risk TIA by the Food and Drug Administration.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. McEwan, O. Darlington, M. Knutsson, H. Denison, P. Ladenvall, P. Amarenco, S.C. Johnston, S. Evans, S. James, A. Himmelmann, J. Venditto, C. Mellstrom, N. Atreja, A. Tank Source Type: research
Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior reduction in the risk of stroke, systemic embolism, mortality, and major bleeding irrespective of kidney function.
Source: Value in Health - July 24, 2018 Category: International Medicine & Public Health Authors: Shoroq M. Altawalbeh, Osama Y. Alshogran, Kenneth J. Smith Source Type: research
Cost-Effectiveness of Edoxaban In Patients With Non-Valvular Atrial Fibrillation In Hong Kong
Atrial fibrillation (AF) is a common arrhythmia associated with debilitating consequences such as stroke, heart failure and venous thromboembolism. In HK, 20-25% of stroke cases are related to AF leading to a significant burden. Warfarin has been the frontline oral anticoagulant for AF but with high bleeding risk and hence monitoring and dose adjustment are required. The non-vitamin-K antagonist oral anticoagulants (NOACs) are alternatives to warfarin for preventing stroke and systemic embolism in non-valvular AF (NVAF) patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: DB Wu, WY Choon, KK Lee Source Type: research
Preliminary Results of Restarting Oral Anticoagulant Treatment In Patients with Non-Valvular Atrial Fibrillation Following Intracranial Hemorrhage: A Population-Based Cohort Study
Patients with non-valvular atrial fibrillation (AF) who survive an intracranial hemorrhage (ICH) have an increased risk of ischemic stroke and thromboembolic events (Stroke/SE). An unanswered question is the efficacy and safety of restarting oral anticoagulant treatment (OAC), relative to not restarting in those patients. Our aim was to investigate if restarting OAC among AF patients with an ICH is linked with a lower risk of Stroke/SE and all-cause mortality, but with a small increase in major bleeding compared to not restarting OAC.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: S Perreault, R C ôté, B White-Guay, M Dorais Source Type: research
Long-Term Health Benefits of Treating Non-Valvular Atrial Fibrillation with Apixaban Versus Vitamin K Antagonists In Germany: A Population-Based Modelling Study
Patients with non-valvular atrial fibrillation (NVAF) are five times more likely to suffer a stroke, resulting in enormous personal, social and economic costs. For more than 50 years, vitamin K antagonists (VKAs) have been the primary medication for stroke prevention. Nevertheless, VKA therapy requires frequent monitoring, is limited by a narrow therapeutic window and is associated with an increased risk of bleeding. Apixaban, a non-vitamin K oral anticoagulant (NOAC), has shown superior efficacy and reduced risk of major bleeding compared to VKA in the ARISTOTLE trial.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Mueller, S Himmler, E Basic, E Hradetzky Source Type: research
Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research
Effectiveness And Safety Of Reduced Dose Non-Vitamin K Antagonist Oral Anticoagulants In Patients Without Severe Renal Impairment
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has been a major advance for stroke prevention in atrial fibrillation. Because NOACs have significant renal clearance, dose reduction is needed in patients with severe kidney disease. However, some physicians may prescribe reduced-dose NOACs to patients with relatively good renal function due to the concerns over the bleeding risk. We sought to investigate the use and clinical outcomes of reduced-dose NOACs in patients without severe renal impairment.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: X. Yao, N.D. Shah, L.R. Sangaralingham, B.J. Gersh Source Type: research
Apixaban In Patients With Atrial Fibrillation: Patient Characteristics Of The Latin America Cohort From A Multinational Clinical Trial
Patients with Atrial fibrillation (AF), have a five-fold increase in the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism reduction without impacting the risk of major bleeding or intracranial hemorrhage. Patient characteristics of the Latin America (LA) cohort and overall population are presented.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Avezum, MC Bahit, JA Hermosillo, FL Zanetti, P Perafan, A Juarez-Garcia, C Vulcano, LA Cubillos, BM Korenblat Donato Source Type: research
